In 2020, the global cancer cell market is predicted to be worth US$ 8,525.5 million, growing at a CAGR of 8.20 percent over the forecast period (2020-2027).

Cancer cells differ from normal cells in that a succession of mutations can cause a normal cell to continue to expand and divide out of control, resulting in the formation of cancerous cells. Cancer cells, unlike regular cells, have the potential to move or infiltrate surrounding tissues and so spread to different parts of the body, whereas normal cells stay in the area where they started. A cascade of genetic and epigenetic alterations causes cancer cells to form in the human body. Some of these changes can be inherited or, more commonly, triggered by carcinogens (substances that cause cancer), such as tobacco.

During the projected period, the worldwide Cancer Cell Market is expected to rise due to the rising prevalence of cancers such as lung cancer, breast cancer, and others. For example, according to a World Health Organization report issued in 2018, cancer is the second biggest cause of mortality in individuals worldwide, accounting for about 9.6 million fatalities in 2018.

Furthermore, the market is expected to grow due to key companies focusing on inorganic strategies such as mergers and acquisitions to launch new targeted cell therapies for the treatment of cancer patients. Pfizer, for example, announced a merger with Allogene in 2018 to develop investigational CAR-T cell therapy for Cancer Cell Market treatment.

Coronavirus's Impact on the Global Cancer Cell Market (COVID-19)

COVID-19 has expanded to over 100 nations since its outbreak in December 2019, prompting the World Health Organization to designate it as a public health emergency. According to a study from the World Health Organization, the coronavirus (COVID-19) has infected about 67 million people worldwide as of December 7, 2020.

The coronavirus (COVID-19) pandemic and subsequent lockdown in several nations around the world have had a financial impact on key cancer cell firms. The private healthcare sector is one of the areas where the COVID-19 epidemic has had a significant impact.

Players to Watch

Abbott Laboratories, Novartis International AG, Arcellx, Autolus Therapeutics, Kite Pharma, Cellectis, Celyad Oncology, Crescendo Biologics Limited, GammaDelta Therapeutics Ltd., Bio-Rad Laboratories Inc, QIAGEN Inc, Thermo Fisher Scientific, Merck Millipore, Siemens Healthineers AG, and GE Healthcare are among the major players in the global cancer cell market.